GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Key claim: A prospective descriptive study will track muscle mass, strength, physical performance, and sarcopenia risk at baseline and 3 months in non-diabetic obese adults starting GLP-1 RA therapy to relate weight loss to body-composition changes.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.
Why this matters
A prospective descriptive study will track muscle mass, strength, physical performance, and sarcopenia risk at baseline and 3 months in non-diabetic obese adults starting GLP-1 RA therapy to relate weight loss to body-composition changes.